N ATURALLY occurring thyroid hormones and a number of synthetic thyromiinetic analogs have been shown to influence serumlipid levels in man and in laboratory animals. 1 " 6 Chaikoff et al. 1 and Danowski and coworkers 2 have observed that the serum lipids of the dog are significantly altered by the level of circulating thyroid hormone. Although the dog is less dependent on thyroid hormone for control of metabolic processes than is man, 2 its serum cholesterol and other circulating lipids can be markedly altered by the administration of thyromimetie agents. This experiment was designed to measure the relative effectiveness of the chronic oral administration of D-and L-3,5,3'-triiodothyronine on the cireulating-lipid patterns of intact, naturally hypereholesteremic dogs.
Methods
Naturally hypercholesteremic adult mongrel dogs (screened for elevated plasma total cholesterol) were housed individually in metabolism-type cages and received a uniform, caloric-controlled diet.
The diet offered the dogs consisted of one-half can of commercial dog food (approximately 260 calories) and an enriched whole-milk blend (approximately 500 to 750 calories per dog, depending on the size of the animal-average, 800 ml./dog). The amount of food was adjusted to supply a slight excess of calories based on the calculated surface area of each dog. 7 The food was offered once daily in the morning, and any food not consumed within three hours was removed. Tap water was supplied ad libitum. The dogs were maintained in a controlled environment (76 ± 2 P. and 50 per cent humidity). Dogs were weighed weekly prior to feeding, and food consumption was determined periodically.
The formula of the milk supplement was as follows (per cent) : powdered whole milk, 87; cellulose (Alphaeel), 7.5; trace-salt-sucrose mix (trace salts, USP X I V [1950] , 65 Gm. mixed with 1,935 Gm. sucrose), 4; vitamins A and Dsucrose mix (vitamin A, 500,000 USP units/Gm., and vitamin D, 50,000 USP units/Gm.,* 8 Gm. mixed with 1,992 Gm. sucrose), 0.5; and vitamin E acetate,t 300 Gm. mixed with 1,700 Gm. sucrose, 1.0. The final diet was prepared in batches containing the following: dry mix listed above, 360 Gm.; cottonseed oil, 25 ml., coconut oil, 25 ml.; and water, 2,400 ml. The mixture was blended for one minute in a large Waring blender.
Twenty dogs were assigned to five groups of four dogs each (two of each sex) and were administered the following /xg./Kg. dose levels/ dog for 21 weeks: placebo (group T) ; D-3,5,3'triiodothyronine ( D -T 3 ) , 60 (group I I ) and 240 (group I I I ) ; and L-3,5,3'-triiodothyronine ( L -T 3 ) , 4 (group IV) and 16 (group V ) . During the subsequent 10 weeks, daily dosages of drugs for each group were doubled.
The drugs were suitably diluted with terra alba and administered in gelatin capsules in the morning and late afternoon, except on week ends when capsules were administered only in the morning. Equal numbers of placebo capsules were administered to control dogs.
Dogs were bled at intervals spaced in such a way that samples for any one test were obtained on the same day of each week. Dogs were bled from the femoral vein prior to the morning feeding.
The following blood-lipid determinations were performed: plasma total cholesterol, 8 plasma free and esterified cholesterol, 8 plasma total lipids, 0 plasma phospholipids, 10 and plasma triglyeerides. 11 The following functional tests were performed: bromsulphalein clearance, 1 -alkaline phosphatase (Phosphatabst), 13 bound iodine (PBI), 1(i prothroinbin clotting time, 17 glucose tolerance test, 18 plasma urea nitrogen (Urograph*), 19 and plasma sodium and potassium levels by flame photometry. Total blood profiles were determined at frequent intervals during the experiment.
Autopsies were performed at the end of 31 weeks of treatment. Gross pathological examination was made of the vital organs, and total lipid and cholesterol determinations were made on the livers, aortas, and adrenals.
Results

Plasma Total Cholesterol
Plasma total cholesterol of the control dogs (group I) increased only 6 per cent during the 31-week experimental period. D-T 3; administered during the first 21 weeks at levels of 60 (group II) and 240 (group III) jig./ Kg./day, caused plasma total-cholesterol reductions of 22 and 25 per cent, respectively. Doubling each dose of D-T 3 during the last 10 weeks of the experiment (weeks 21 to 31)
•Warner-Chilcott Laboratories, Morris Plains, New Jersev. produced no further reduction for group II animals, but decreased plasma total cholesterol 33 per cent of the baseline value for group III animals. L-T 3 , administered during the first 21 weeks at levels of 4 (group IV) and 16 (group V) /xg./Kg./day, caused plasma total-cholesterol reductions of 3 and 15 per cent, respectively. Doubling each dose of L-T 3 during the last 10 weeks of the experiment produced no further reduction for group IV animals, but decreased plasma total cholesterol 30 per cent of the baseline value for group V animals.
Plasma Free and Esterified Cholesterol
At the end of 21 and 29 weeks of chronic administration of D-and L-T 3 , no differences in percentages of free or esterified plasma cholesterol were observed for any of the treated groups when compared with those of the control group (table 1) .
Plasma total lipids of the control dogs (group I) decreased 10 per cent during the first 21 weeks and 12 per cent of the baseline by the end of the 31-week experimental pe- 
Plasma Phospholipids
During the first 21 weeks, dogs receiving L-T 3 (groups IV and V) showed no significant changes in plasma phospholipids from the values obtained in control dogs (group I).
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During the last 10 weeks of the experiment, after the doubling of the dose of L-T 3 in each group, only group V dogs had values appreciably less than those of controls. At all doses tested, during the 31-week experimental period, groups receiving D-T3 showed consistently greater depression of plasma-phospholipid levels than did the control group.
Plasma Triglyeerides
Since baseline plasma-triglyeeride values were not obtained for the experimental dogs, it is necessary to compare the values for the treated dogs during the experiment with those of the control group at any test period. During the sixteenth to twenty-ninth weeks, little or no differences in plasma triglyeerides from the control levels (table 2) were observed. 
Physiological Tests
Bromsulphalein clearance was determined at the end of the twenty-first and twentyninth weeks of the experiment. Mean control values (per cent retention at one-half hour) were 4.2 and 4.0, respectively, for the two tests. The values of the thyrominietic-treated group ranged from 3.1 to 4.2 and were not significantly different from control values.
Serum alkaline-phosphatase values were determined on all dogs at four-week intervals and remained at consistent normal levels throughout the entire experiment. There was a tendency for a slight elevation in alkaline phosphat&se in the dogs in groups III and V receiving the highest levels of D-T 3 and L-T3, respectively. No single value, as determined either by the Phosphatab method 13 or the Bodansky method, 20 approached the "pathological range" (table 3) .
Levels of protein-bound iodine in the control dogs were unchanged throughout the experimental period. The highest level of L-T3 administered (group V) caused a significant (P < 0.05) reduction in PBI levels (table 4) .
No significant differences from control values were observed in auy of the experimental groups tested by the following: prothrombin clotting time (at four-week intervals) ; glucose tolerance (twentieth week); plasma urea nitrogen (twenty-first week); plasma sodium and potassium levels (twentieth and twenty-ninth weeks) ; and serum glutamic oxalacetic transaminase (at four-week intervals for the first 20 weeks).
Urine was collected at four-week intervals and analyzed for albumin, glucose, bilirubin, occult blood, and microscopic analysis. All tests were negative.
Total blood studies (red blood count, white blood count, hemoglobin, hematocrit, and differential) were made at 0, 17, and 29 weeks of the experimental period. No significant differences from control values were observed in any of the blood studies.
Weight and Food Consumption
All animals on this experiment gained weight. Dogs receiving the higher level of n-T s (group III) consistently resisted this trend to gain weight but did not lose weight. Food-consumption data indicated that D-T3 was not an appetite depressant, since calories consumed/Kg, body weight for these dogs were similar to calories consumed by the controls and the L-T 3 -treated animals.
Postmortem Evaluation
After the dogs had been chronically treated for 31 weeks with D-or L-T 3 at the prescribed dosage levels, they were examined for postmortem evaluation. Sections of the livers, adrenals, and aortas were removed for analysis of cholesterol, total lipid, and, in the aortas, sudanophilia.
No significant differences were noted in the cholesterol content of any of the organs ana- lyzed (table 5). Dogs that received the highest level of L-T 3 (group V) had the lowest amount of cholesterol m these organs.
Gross pathological examination of the livers of the experimental dogs revealed no evidence of necrosis or fatty infiltration. No significant differences in total liver lipids were noted (table 5 ).
An appropriate length of aorta was selected from each dog for examination of evidence of sudanophilia. Aortas were stained with Sudan IV and counterstained with malachite green. No visible evidence of sudanophilia was observed in any of the dog aortas.
Discussion
Both D-T 3 and L-T 3 significantly altered the blood-lipid patterns of hypercholesteremic dogs. The doses chosen were based on the equivalent effects of the two compounds in lowering blood cholesterols in rats. In the dog, the 4 jug./Kg./day level of L-T 3 had no depressing effect on plasma total-cholesterol levels. The doubling of this dose after 21 weeks still caused no cholesterol-depressing effects. However, 16 jug. of L-T 3 /Kg./day was an effective level for lowering plasma total cholesterol, and doubling this dose caused still greater depressing effects. It may, therefore, be concluded that, in dogs under the conditions of this experiment, the minimum effective plasma cholesterol-depressing dose with L-T 3 lies between 8 and 16 /^g./Kg./day. Since both levels of D-T 3 were effective in lowering plasma total-cholesterol values, the minimum effective dose is not so clearly discernible; however, the 60 jug./Kg./day level seemed to be fairly equivalent to the lowering effect of Circulation Reiearch, Volume IX, September 1961 16 ^.g. of L-T 3 . Although individual-dog data have not been presented, it was noted that those dogs with the lowest initial plasma totalcholesterol levels tended to be the least responsive to either of the two test compounds.
The two compounds studied had relatively the same depressing effects on plasma total lipid as they had on plasma total cholesterols.
Significant reductions in plasma phospholipids were observed for both levels of D-T 3 and for the higher level of L-T 3 after the dosage level had been doubled at the end of the twenty-first week. Doubling the dosage levels of D-T 3 at the end of the twenty-first week produced no further reduction in plasma-phospholipid levels. Unlike the significant reduction in plasma total cholesterol after the doubling of the D-T 3 dosage levels, plasma phospholipids exhibited complete resistance to further reduction, thereby producing a more favorable cholesterol/phospholipid ratio. No pretreatment plasma-triglyceride values are available; however, average values for treated dogs were not significantly different from those of control dogs run concurrently after 21 weeks of treatment. No significant changes in triglyceride values were noted after 29 weeks of treatment when compared with the results obtained at 21 weeks (prior to doubling drug levels).
Throughout the entire experiment, all dogs remained in good health, as judged by gross appearances and actions. Dogs receiving D-T 3 gained less weight than did either the controls or the L-T 3 -treated groups. The amount of food given to each dog was calculated to be slightly in excess of a maintenance level. Since all dogs, generally throughout the experiment, ate all the food offered, the differences in the effects of the two compounds in weight gains would appear to have metabolic significance. It is not possible, from these data, to speculate on the effect the compounds might have had on weight gains if the dogs had been fed ad libitum.
These physiological and metabolic functional tests determined on the dogs at intervals during the experimental period indicated that no abnormal changes occurred during the administration of the compounds. One of two changes noted in the tests was that several alterations from average baseline values were observed in the values obtained for plasma alkaline phosphatase after the dosage levels of the compounds had been doubled, and only with the highest levels of the two compounds. The alkaline-phosphatase levels were only slightly elevated and did not approach the usual indicated pathological range. The second noticeable change in functional tests was on protein-bound-iodine levels, which were definitely depressed by both levels of L-T 3 . There was a trend for D-T 3 to increase the PBI in direct proportion to the dose of the compound.
After autopsy of the dogs treated chronically with D-or L-T 3 for 31 weeks, evaluation of liver total lipids and of the cholesterol contents of aortas, adrenals, and livers revealed no significant differences between treated and control groups. The extreme resistance of dogs to the development of fatty infiltration of the aorta is attested to by the fact that all of the experimental hypercholestereniic dogs, including the controls, were negative for sudanophilia.
The results of this experiment confirm the earlier observation of Danowski et al. 2 that the dog is highly resistant to symptoms of thyrotoxicosis induced by high levels of exogenously administered thyromimetie agents. L-T3 at approximately 25 times the estimated daily dose required to control human myxedema had no effect on weight gain of the dogs. Dauowski concludes from his work that the dog is more tolerant to thyromimetie agents than is man because of the dog's ability to more rapidly inactivate and excrete these agents.
None of the dosage levels of thyromimetie agents used during this experiment caused a loss in body weights of the dogs from pretreatment values. However, D-T 3 at the levels administered caused a retardation in the rate of body weight gain when compared with that of the untreated controls. A noticeable retardation in weight gain was caused by the administration of the higher level of L-T3; however, this effect appeared to be less marked than for either of the dosage levels of D-T3. The retardation in the rate. of weight gain appears to be a result of alteration in metabolism rather than a result of depression of appetite, since isocaloric diets were administered and consumed by each dog on the basis of calculations of normal caloric requirements. 7 Although there may not be a basis for a relationship between retardation of body weight gain and the effectiveness of these agents as plasma cholesterol-lowering agents, the effectiveness of D-and L-T3 under the conditions of this experiment on these two parameters was closely parallel.
Summary
Twenty intact, naturally hypercholestereniic dogs were divided into five groups and chronically administered D-3,5,3'-triiodothyronine (D-T 3 ) and L-3,5,3'-triiodothyronine (L-T 3 ) at two levels, respectively, for 31 weeks. The administration of the drugs was divided into two periods, the first for 21 weeks, after which the dosage level for each of the four test groups was doubled for an additional 10 weeks. Plasma total cholesterol, total lipids, and phospholipids were significantly lowered by the administration at both levels of D-T 3 and the higher level of L-T 3 . At the end of 21 and 29 weeks of thyromimetie administration, no differences in percentage of free or esterified cholesterol were observed for any of the treated groups when compared with the control groups. A battery of physiological and functional tests was performed at suitable intervals throughout the experimen-
Research, Volume IX, September 1961
tal period with no evidence of abnormalities due to the administration of the thyroinimetie agents. The only significant functional change measured was a reduction in protein-boundiodine levels in the clogs receiving the higher level of JL-T 3 .
Throughout the entire experiment, all dogs remained in good health as judged by gross appearances and actions. The dogs receiving D-T 3 gained less weight than did either the controls or the L-T 3 -treated groups, even though all animals ate isocaloric balanced diets. At post mortem, after 31 weeks of chronic thyroinimetie administration, gross pathology was negative; chemical analyses of cholesterol content of aortas, adrenals, and livers indicated no significant differences. Analyses of livers for total lipids showed no significant differences, and no evidence of aortic sudanophilia was apparent in any of the experimental dogs.
